92 related articles for article (PubMed ID: 9969455)
1. Alpha decay of 231U to levels in 227Th.
Liang CF; Sheline RK; Paris P; Hussonois M; Ledu JF; Isabelle DB
Phys Rev C Nucl Phys; 1994 Apr; 49(4):2230-2232. PubMed ID: 9969455
[No Abstract] [Full Text] [Related]
2. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
Dahle J; Bruland OS; Larsen RH
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):186-92. PubMed ID: 18722269
[TBL] [Abstract][Full Text] [Related]
3. Osteosarcoma risk after simultaneous incorporation of the long-lived radionuclide 227Ac and the short-lived radionuclide 227Th.
Müller WA; Murray AB; Linzner U; Luz A
Radiat Res; 1990 Jan; 121(1):14-20. PubMed ID: 2300664
[TBL] [Abstract][Full Text] [Related]
4. 227Th-EDTMP: a potential therapeutic agent for bone metastasis.
Washiyama K; Amano R; Sasaki J; Kinuya S; Tonami N; Shiokawa Y; Mitsugashira T
Nucl Med Biol; 2004 Oct; 31(7):901-8. PubMed ID: 15464392
[TBL] [Abstract][Full Text] [Related]
5. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.
Henriksen G; Bruland OS; Larsen RH
Anticancer Res; 2004; 24(1):101-5. PubMed ID: 15015582
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.
Melhus KB; Larsen RH; Stokke T; Kaalhus O; Selbo PK; Dahle J
Cancer Biother Radiopharm; 2007 Aug; 22(4):469-79. PubMed ID: 17803441
[TBL] [Abstract][Full Text] [Related]
7. American Chemical Society--227th Annual Meeting. Antibacterials and anti-inflammatories. 28 March - 1 April 2004, Anaheim, CA, USA.
Garvey R; Veryard C
IDrugs; 2004 May; 7(5):420-2. PubMed ID: 15154097
[No Abstract] [Full Text] [Related]
8. [The Proceedings of the 227th Kanto-Koshinetsu Regional Meeting of the Japanese Society of Neurology].
Rinsho Shinkeigaku; 2019; 59(4):215-228. PubMed ID: 31019182
[No Abstract] [Full Text] [Related]
9. Level structure and reflection asymmetry in 227Th.
Liang CF; Paris P; Sheline RK; Nosek D; Kvasil J
Phys Rev C Nucl Phys; 1995 Mar; 51(3):1199-1210. PubMed ID: 9970169
[No Abstract] [Full Text] [Related]
10. Late effects after incorporation of the short-lived alpha-emitters 224Ra and 227Th in mice.
Müller WA; Gössner W; Hug O; Luz A
Health Phys; 1978 Jul; 35(1):33-55. PubMed ID: 102611
[No Abstract] [Full Text] [Related]
11. American Chemical Society--227th annual meeting. Diabetes. 28 March - 1 April 2004, Anaheim, CA, USA.
Rotella DP
IDrugs; 2004 May; 7(5):428-9. PubMed ID: 15154100
[No Abstract] [Full Text] [Related]
12. Further reports on the relation between Arakawa's reaction and thiamine content of human milk. Part 2. Bound thiamine of human milk; 227th report of the peroxidase reaction.
NAITO T
Tohoku J Exp Med; 1952 Jun; 56(1-2):23-9. PubMed ID: 13005481
[No Abstract] [Full Text] [Related]
13. American Chemical Society--227th Annual Meeting. NMDA receptor. 28 March - 1 April 2004, Anaheim, CA, USA.
Rotella DP
IDrugs; 2004 May; 7(5):433-5. PubMed ID: 15154102
[No Abstract] [Full Text] [Related]
14. American Chemical Society--227th annual meeting. Highlights. 28 March - 1 April 2004, Anaheim, CA, USA.
Garvey R; Veryard C
IDrugs; 2004 May; 7(5):426-7. PubMed ID: 15154099
[No Abstract] [Full Text] [Related]
15. American Chemical Society--227th Annual Meeting. New disclosures. 28 March - 1 April 2004, Anaheim, CA, USA.
Garvey R; Veryard C
IDrugs; 2004 May; 7(5):423-5. PubMed ID: 15154098
[No Abstract] [Full Text] [Related]
16. American Chemical Society--227th annual meeting. Neuroprotection. 28 March - 1 April 2004, Anaheim, CA, USA.
Rotella DP
IDrugs; 2004 May; 7(5):430-2. PubMed ID: 15154101
[No Abstract] [Full Text] [Related]
17. Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation.
Staudacher AH; Bezak E; Borysenko A; Brown MP
Nucl Med Commun; 2014 Dec; 35(12):1284-90. PubMed ID: 25192189
[TBL] [Abstract][Full Text] [Related]
18. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
[TBL] [Abstract][Full Text] [Related]
19. Superallowed α Decay to Doubly Magic ^{100}Sn.
Auranen K; Seweryniak D; Albers M; Ayangeakaa AD; Bottoni S; Carpenter MP; Chiara CJ; Copp P; David HM; Doherty DT; Harker J; Hoffman CR; Janssens RVF; Khoo TL; Kuvin SA; Lauritsen T; Lotay G; Rogers AM; Sethi J; Scholey C; Talwar R; Walters WB; Woods PJ; Zhu S
Phys Rev Lett; 2018 Nov; 121(18):182501. PubMed ID: 30444390
[TBL] [Abstract][Full Text] [Related]
20. Development of separation technology for the removal of radium-223 from decayed thorium-227 in drug formulations. Material screening and method development.
Frenvik JO; Kristensen S; Ryan OB
Drug Dev Ind Pharm; 2016 Aug; 42(8):1215-24. PubMed ID: 26569601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
